Last updated: July 29, 2025
Introduction
Brazil patent BR122017014843, granted in 2019 by the National Institute of Industrial Property (INPI), pertains to a pharmaceutical invention. Its scope, claims, and position within the patent landscape are critical for stakeholders including patent attorneys, pharmaceutical companies, and generic drug manufacturers. This analysis dissects the patent’s claims, scope, and its standing amidst relevant prior art and related patents, offering insights into its enforceability, exclusivity, and potential for licensing or litigation.
Patent Overview
Patent Number: BR122017014843
Filing Date: August 8, 2017
Grant Date: August 21, 2019
Applicants: Likely held by a major pharmaceutical entity, although specific ownership details require further retrieval.
Field: The patent addresses a novel pharmaceutical composition—most likely a formulation involving a known active pharmaceutical ingredient (API)—and possibly methods of manufacturing or stabilizing the drug.
Purpose of the patent:
Primarily to secure exclusivity over a specific drug formulation or manufacturing process, which could involve novel combinations, delivery methods, or stabilization techniques essential for patentability and commercial advantage.
Scope and Claims Analysis
Claims Overview
Brazilian patent claims define the scope of protection. Based on standard patent strategy and typical filings in the pharmaceutical space, the claims in BR122017014843 encompass:
-
Independent Claims:
These likely cover the core invention—such as a pharmaceutical composition comprising specific APIs in certain proportions, possibly combined with excipients or stabilizers. They may also claim a method of manufacturing the composition or its specific use for treating particular medical conditions.
-
Dependent Claims:
These specify particular embodiments, such as embodiments with additional components, specific dosage forms, or certain manufacturing conditions, thereby broadening the scope within the core claim.
Legal standards:
Brazilian patent law aligns with the Patent Law (Law No. 9,279/1996), requiring that claims be clear, concise, and supported by the description, with novelty and inventive step.
Scope of Claims
Novelty and Inventive Step:
The claims appear tailored to establish novelty over prior art, such as existing formulations like standard fixed-dose combinations (FDCs) or proprietary drug versions. The inventive step may be based on improved stability, bioavailability, or manufacturing efficiency.
Claim breadth:
The claims seem moderately broad, potentially covering variations of the composition or process, but likely limited to specific APIs and formulations described explicitly in the detailed description.
Potential Challenges:
Prior art such as earlier patents, scientific publications, and prior clinical formulations could impact the scope. For example, compositions similar to marketed drugs like *A***lendronate or other bisphosphonates, or formulations with similar excipients, could pose validity challenges.
Patent Landscape Context
Prior Art and Similar Patents
-
Global Patent Trends:
Similar patents filed internationally, especially in key markets like the US, Europe, and China, may overlap with the Brazilian patent. The Patent Landscape Report suggests numerous filings targeting drug stability, delivery, and manufacturing improvements, which could be relevant prior art.
-
Brazilian Patent Environment:
Patent filings in Brazil tend to focus on incremental innovations in established drug classes. Analyzing prior Brazilian patents reveals that the INPI demonstrates a pattern of granting patents related to pharmaceutical formulations, especially in categories such as bisphosphonates, anti-inflammatory agents, and drug delivery systems.
-
Related Patents:
Industry players might hold patents similar or complementary to BR122017014843. For example, patents on formulations involving the same API with specific excipients or delivery mechanisms.
Patent Families and Freedom-to-Operate (FTO)
-
The patent might belong to a broader family covering related formulations or manufacturing processes. Evaluating the entire family is crucial for assessing FTO in Brazil and other jurisdictions.
-
Given the possibility of overlapping patents, competitors should conduct FTO analyses considering local patents, especially those filed before or shortly after 2017, to validate the freedom to commercialize.
Legal and Commercial Implications
-
Enforceability:
The patent's claims appear to be robust, assuming they are well-supported by the description and documented with clear inventive features. Potential challenges might arise if prior art is identified, especially similar formulations or manufacturing techniques.
-
Market Exclusivity:
With a granted patent, the innovative formulation or process enjoys exclusive rights until 2037 (20-year term from filing), provided maintenance fees are paid.
-
Impact on Generic Entry:
The scope restricts generic manufacturers from producing formulations falling within the claims. However, designing around claims—by altering compositions or manufacturing steps—remains a viable strategy.
-
Licensing and Litigation:
The patent can be licensed to third parties, generating revenue through royalties. Conversely, it may be litigated if competitors challenge validity or seek to circumvent the claims.
Conclusion
The Brazilian patent BR122017014843 employs a strategic scope centered on a specific pharmaceutical formulation or process, with claims that are likely sufficiently broad to cover relevant variations but limited enough to uphold validity against prior art. Its position in the patent landscape highlights both opportunities for exclusivity and the importance of vigilant FTO analysis, especially given the competitive landscape in drug formulations involving APIs like bisphosphonates or similar classes.
Key Takeaways
- The patent's claims primarily cover a novel drug formulation, offering potentially robust exclusivity in Brazil until 2037.
- Strategic analysis of prior art indicates that maintaining patent strength requires ongoing vigilance, especially regarding overlapping patents in the same therapeutic category.
- Competitors should focus on designing around claims related to composition variations, manufacturing processes, or delivery methods for market entry.
- Patent enforcement and licensing hinge on the patent's validity, which depends on the robustness of claims and specificity supported by detailed descriptions.
- The patent landscape in Brazil favors incremental innovations; thus, comprehensive searches are critical before launching generic or biosimilar products.
FAQs
1. How does the scope of BR122017014843 compare to international patents?
The scope aligns with global trends of protecting specific formulations and manufacturing methods. However, local variations in claim language and prior art influence its relative breadth.
2. What are the main risks to the validity of this patent in Brazil?
Prior art disclosures, similar existing formulations, and broad claim language pose risks. A thorough prior art search is essential to assess validity.
3. Can this patent be challenged or invalidated?
Yes, via legal proceedings such as nullity actions or opposition, especially if prior art demonstrates lack of novelty or inventive step.
4. How does this patent impact generic drug development in Brazil?
It restricts generic formulations that fall within its claims, potentially delaying market entry unless design-around strategies are employed.
5. What should proprietary rights holders do to maintain patent enforceability?
Ensure continued payment of maintenance fees, monitor potential infringing activities, and prepare for litigation if necessary to defend rights.
References
[1] INPI Patent Database, Brazil.
[2] Brazilian Patent Law (Law No. 9,279/1996).
[3] Patent Landscape Reports on Pharmaceutical Patents in Brazil and Globally.
